Videos
PCI Launches New Returns Management Facility
PCI Launches New Returns Management Facility
Purpose-built, high-spec unit to process return drugs from clinical trials
10.18.18
PCI Clinical Services has completed a dedicated Returns Management facility at its Clinical Services Center of Excellence at Bridgend, UK.
PCI provides a full service Returns Management service for clients, providing visibility and accountability in returning investigational drug product from investigational sites at the conclusion of a clinical study. Returning and reconciling Investigational Medicinal Product (IMP) on completion of a study is a critical part of a Clinical trial and can require complex reverse logistics. Trial outcomes can be impacted if Returns are not processed efficiently and precisely.
The new, custom fit facility enhances PCI’s expansive Clinical Storage and Distribution presence in Bridgend. The development reinforces the organization’s ongoing investment in and expansion of its global Clinical Services network, reflecting PCI’s long-term commitment to ensuring successful Clinical study outcomes for its clients; enabling successful commercialization of drug products and ultimately speed-to-market for potentially life-saving treatments.
Bridgend is one of PCI’s eight global facilities supporting medicines which are distributed to over 100 countries worldwide. This latest addition to PCI’s Clinical Services Center of Excellence provides a modern, high-spec unit, purpose-built to process Return drugs from Clinical trials in a dedicated facility. It complements PCI’s existing facilities at Bridgend, which are currently used for specialist Clinical trial logistics as well as Packaging, Labeling and Qualified Person activities for Investigational Medicinal Products.
PCI’s Kevin Williams, clinical site leader for the Bridgend facility, said, “The Returns process can involve thousands of product packages from investigational sites around the world. Each of these must be stringently accounted for, sometimes down to individual dose level. Any discrepancies can tie up valuable time and resources, potentially inhibiting the formal close of the study and progression of the drug in its development.”
PCI’s new Returns Management facility follows other recent investments at the Bridgend location. PCI announced a site expansion with a new 37,500 square foot building which opened in January 2018, expanding its Clinical trial services campus in Bridgend.
PCI provides a full service Returns Management service for clients, providing visibility and accountability in returning investigational drug product from investigational sites at the conclusion of a clinical study. Returning and reconciling Investigational Medicinal Product (IMP) on completion of a study is a critical part of a Clinical trial and can require complex reverse logistics. Trial outcomes can be impacted if Returns are not processed efficiently and precisely.
The new, custom fit facility enhances PCI’s expansive Clinical Storage and Distribution presence in Bridgend. The development reinforces the organization’s ongoing investment in and expansion of its global Clinical Services network, reflecting PCI’s long-term commitment to ensuring successful Clinical study outcomes for its clients; enabling successful commercialization of drug products and ultimately speed-to-market for potentially life-saving treatments.
Bridgend is one of PCI’s eight global facilities supporting medicines which are distributed to over 100 countries worldwide. This latest addition to PCI’s Clinical Services Center of Excellence provides a modern, high-spec unit, purpose-built to process Return drugs from Clinical trials in a dedicated facility. It complements PCI’s existing facilities at Bridgend, which are currently used for specialist Clinical trial logistics as well as Packaging, Labeling and Qualified Person activities for Investigational Medicinal Products.
PCI’s Kevin Williams, clinical site leader for the Bridgend facility, said, “The Returns process can involve thousands of product packages from investigational sites around the world. Each of these must be stringently accounted for, sometimes down to individual dose level. Any discrepancies can tie up valuable time and resources, potentially inhibiting the formal close of the study and progression of the drug in its development.”
PCI’s new Returns Management facility follows other recent investments at the Bridgend location. PCI announced a site expansion with a new 37,500 square foot building which opened in January 2018, expanding its Clinical trial services campus in Bridgend.
Related Searches:
